Form 13-F position report

IMMUNITYBIO INC COM (DE)

Reported by SUSQUEHANNA INTERNATIONAL GROUP LLP

IBRX CUSIP 45256X103 Manager CIK 0001446194

Reported 360,213 shares, down 74,960 (17.2%) from the prior quarter.

Reported value 26.4%; share count -17.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 360,213 Quarter-end amount reported
Reported value $1,001,392 Fair value at quarter end
Consecutive quarters held 10 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 8624000
2021-12-31 5772000
2022-03-31 4291000
2022-06-30 2138000
2022-09-30 3135000
2022-12-31 2139535
2023-03-31 792015
2023-06-30 1001392
2023-09-30 773398
2023-12-31 933921
2024-03-31 598154
2024-06-30 2395918
2024-09-30 1555172
2024-12-31 1443612
2025-03-31 2328148
2025-06-30 4889037
2025-09-30 6500929
2025-12-31 7235908
2026-03-31 9045047
2026-06-30 577488

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for IMMUNITYBIO INC COM (DE) held by SUSQUEHANNA INTERNATIONAL GROUP LLP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 65,961 -1,113,315 (-94.4%) < 0.01% $577,488 2026-08-14
Q1 2026 Reduced 1,179,276 -2,475,223 (-67.7%) < 0.01% $9,045,047 2026-05-15
Q4 2025 Added 3,654,499 +1,011,845 (38.3%) < 0.01% $7,235,908 2026-02-17
Q3 2025 Added 2,642,654 +790,746 (42.7%) < 0.01% $6,500,929 2025-11-14
Q2 2025 Added 1,851,908 +1,078,437 (139.4%) < 0.01% $4,889,037 2025-08-14
Q1 2025 Added 773,471 +209,560 (37.2%) < 0.01% $2,328,148 2025-05-14
Q4 2024 Added 563,911 +145,854 (34.9%) < 0.01% $1,443,612 2025-02-14
Q3 2024 Added 418,057 +38,956 (10.3%) < 0.01% $1,555,172 2024-11-14
Q2 2024 Added 379,101 +267,713 (240.3%) < 0.01% $2,395,918 2024-08-15
Q1 2024 Reduced 111,388 -74,652 (-40.1%) < 0.01% $598,154 2024-05-07
Q4 2023 Reduced 186,040 -271,592 (-59.3%) < 0.01% $933,921 2024-02-14
Q3 2023 Added 457,632 +97,419 (27.0%) < 0.01% $773,398 2023-11-14
Q2 2023 Reduced 360,213 -74,960 (-17.2%) < 0.01% $1,001,392 2023-08-11
Q1 2023 Added 435,173 +13,174 (3.1%) < 0.01% $792,015 2023-05-16
Q4 2022 Reduced 421,999 -208,767 (-33.1%) < 0.01% $2,139,535 2023-02-14
Q3 2022 Added 630,766 +56,047 (9.8%) < 0.01% $3,135,000 2022-11-14
Q2 2022 Reduced 574,719 -190,221 (-24.9%) < 0.01% $2,138,000 2022-08-15
Q1 2022 Reduced 764,940 -184,486 (-19.4%) < 0.01% $4,291,000 2022-05-16
Q4 2021 Added 949,426 +63,982 (7.2%) < 0.01% $5,772,000 2022-02-14
Q3 2021 Added 885,444 +120,263 (15.7%) < 0.01% $8,624,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

161 managers reported IMMUNITYBIO INC COM (DE) for Q2 2023.

Managers reporting IMMUNITYBIO INC COM (DE) in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 10,333,301 +2,047,343 < 0.01% $28,726,578 10 qtrs
BlackRock Inc Added 9,498,666 +2,533,147 < 0.01% $26,406,292 10 qtrs
STATE STREET CORPORATION Added 2,777,236 +127,423 < 0.01% $7,720,716 10 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,730,452 +784,588 < 0.01% $7,590,656 10 qtrs
JPMorgan Chase & Co Reduced 1,478,953 -134,344 < 0.01% $4,111,489 10 qtrs
NORTHERN TRUST CORPORATION Added 1,161,699 +350,006 < 0.01% $3,229,523 10 qtrs
CREDIT SUISSE AG Added 1,016,494 +126,795 < 0.01% $2,825,854 10 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Added 978,547 +262,912 < 0.01% $2,720,361 10 qtrs
NATIONAL BANK OF CANADA FI Added 795,400 +663,300 < 0.01% $2,179,396 7 qtrs
ALLEN HOLDING INC NY Unchanged 687,571 0 0.26% $1,911,447 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 11, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
360,213
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.